|
|
Volumn 7, Issue 5, 2007, Pages 445-458
|
|
Cost-effectiveness of palivizumab in infancy
|
|
Author keywords
Bronchopulmonary dysplasia; Chronic lung disease; Cost effectiveness analysis; Monoclonal antibody; Palivizumab; Pre term infant; Respiratory syncytial virus; Synagis
|
|
Indexed keywords
ANTIVIRUS AGENT;
HYPERIMMUNE GLOBULIN;
MOTAVIZUMAB;
OXYGEN;
PALIVIZUMAB;
PLACEBO;
RIBAVIRIN;
BRONCHIOLITIS;
CHRONIC LUNG DISEASE;
CLINICAL TRIAL;
COST BENEFIT ANALYSIS;
COST EFFECTIVENESS ANALYSIS;
DRUG BLOOD LEVEL;
DRUG COST;
DRUG DOSE ESCALATION;
DRUG EFFICACY;
DRUG INDICATION;
DRUG SAFETY;
ECONOMIC ASPECT;
ECONOMIC EVALUATION;
HEALTH CARE COST;
HEART DISEASE;
HIGH RISK INFANT;
HOSPITAL COST;
HOSPITAL READMISSION;
HOSPITALIZATION COST;
HUMAN;
INFANT;
INFANT DISEASE;
INFANT MORTALITY;
INFANT NUTRITION;
INJECTION SITE ERYTHEMA;
INTENSIVE CARE;
LENGTH OF STAY;
LONG TERM CARE;
LOWER RESPIRATORY TRACT INFECTION;
MORBIDITY;
NURSING CARE;
OUTCOMES RESEARCH;
OXYGEN THERAPY;
POPULATION RESEARCH;
POSTMARKETING SURVEILLANCE;
PREMATURITY;
RESPIRATORY SYNCYTIAL PNEUMOVIRUS;
REVIEW;
RISK FACTOR;
RISK REDUCTION;
SENSITIVITY ANALYSIS;
SYSTEMATIC REVIEW;
UNITED KINGDOM;
VIRUS INFECTION;
|
|
EID: 36248964226
PISSN: 14737167
EISSN: 17448379
Source Type: Journal
DOI: 10.1586/14737167.7.5.445 Document Type: Review |
|
Times cited : (10)
|
|
References (5)
|
